These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 19484786

  • 1. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S.
    Cancer; 2009 Aug 01; 115(15):3468-74. PubMed ID: 19484786
    [Abstract] [Full Text] [Related]

  • 2. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.
    J Urol; 2006 Sep 01; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [Abstract] [Full Text] [Related]

  • 3. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.
    BJU Int; 2009 Dec 01; 104(11):1637-40. PubMed ID: 19549260
    [Abstract] [Full Text] [Related]

  • 4. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV.
    Clin Genitourin Cancer; 2007 Mar 01; 5(4):271-7. PubMed ID: 17553207
    [Abstract] [Full Text] [Related]

  • 5. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
    Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S, Maeda Y, Kadono Y, Takashima M, Koh E, Namiki M.
    Urology; 2009 Jun 01; 73(6):1342-6. PubMed ID: 19371939
    [Abstract] [Full Text] [Related]

  • 6. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.
    J Urol; 2003 Jun 01; 169(6):2008-12. PubMed ID: 12771706
    [Abstract] [Full Text] [Related]

  • 7. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.
    Urology; 2007 Jul 01; 70(1):122-6. PubMed ID: 17656221
    [Abstract] [Full Text] [Related]

  • 8. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ.
    BJU Int; 2007 Jul 01; 100(1):70-5. PubMed ID: 17552955
    [Abstract] [Full Text] [Related]

  • 9. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P, Hering FO, Bruna P, Meller A, Afonso Y.
    Int J Urol; 2007 Apr 01; 14(4):317-20. PubMed ID: 17470161
    [Abstract] [Full Text] [Related]

  • 10. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Apr 01; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 11. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.
    J Urol; 2009 Nov 01; 182(5):2257-64. PubMed ID: 19758618
    [Abstract] [Full Text] [Related]

  • 12. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep 01; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 13. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug 01; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 14. Long term zoledronic acid during androgen blockade for prostate cancer.
    Casey R, Gesztesi Z, Rochford J.
    Can J Urol; 2010 Jun 01; 17(3):5170-7. PubMed ID: 20566009
    [Abstract] [Full Text] [Related]

  • 15. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
    Kawahara T, Kobayashi T, Nishizawa K, Kobori G, Mitsumori K, Ogura K.
    Hinyokika Kiyo; 2008 Apr 01; 54(4):261-6. PubMed ID: 18516917
    [Abstract] [Full Text] [Related]

  • 16. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.
    Cancer; 2004 Mar 01; 100(5):892-9. PubMed ID: 14983482
    [Abstract] [Full Text] [Related]

  • 17. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
    Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T.
    Urology; 2010 May 01; 75(5):1131-7. PubMed ID: 20163839
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1239-45. PubMed ID: 23265571
    [Abstract] [Full Text] [Related]

  • 19. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, Barkley CS, Bilhartz DL, McWhorter LT, Lacerna LV.
    Urology; 2005 Nov 01; 66(5):1054-9. PubMed ID: 16286123
    [Abstract] [Full Text] [Related]

  • 20. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
    Bruder JM, Ma JZ, Wing N, Basler J, Katselnik D.
    J Clin Densitom; 2006 Nov 01; 9(4):431-7. PubMed ID: 17097529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.